ACADIA Pharmaceuticals Inc at Needham Neuroscience Forum (Virtual) Transcript
Okay, good afternoon, everyone. Welcome to the next session with ACADIA. It's my pleasure to be hosting Steve Davis, who is the CEO of the company as well as the Board member; and Serge Stankovic, who is the Head of R&D of the company. Serge brings a wealth of experience in multiple disciplines: neurology, psychiatry, oncology, cardiology and pain. So, we are looking forward to a rich discussion.
Before we move forward, I just wanted to remind our audience that if you have any questions that you would like me to ask the management team, feel free to send it over to me in the chat. With that, Steve, could you please kick us off with a few comments and overview of the company?
Yeah, thanks so much, Ami. Thanks for having us and thanks for each of you for joining. I'll start with just a little bit of level setting. To deliver on our mission, we are focused on three strategic pillars. The first is to drive growth of our NUPLAZID franchise in Parkinson's disease
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
